Powered by

EuroBiotech Report—EMA-Brexit, AstraZeneca, Juvenescence round, Verona fail and Orchard

Jan 17, 2019 - FierceBiotech
Board and Executive Moves

Welcome to the latest edition of our weekly EuroBiotech Report. Our top stories this week come from the U.K., where drug developers unveiled a mixed bag of news against the backdrop of ongoing political turmoil. Firstly, to the European Medicines Agency, which now expects to retain 75% of its staff as it escapes the turmoil and moves to Amsterdam, emboldening it to predict that its core drug evaluation activities will be unaffected by the relocation. Elsewhere, AstraZeneca lost another employee ...